Please login to the form below

Not currently logged in
Email:
Password:

Jardiance

This page shows the latest Jardiance news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

It also renews hope for the pharma company that it can chase down SGLT2 market leader Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim. ... Like Farxiga, Jardiance received a  fast track review status in June, in both HFrEF and HFpEF,

Latest news

  • Boehringer’s head of pharma heads for the exit Boehringer’s head of pharma heads for the exit

    Allan Hillgrove. Company chairman Christian Boehringer said Hillgrove had made a significant contribution to the launch of new drugs like Ofev (nintedanib) for pulmonary fibrosis and diabetes therapy Jardiance (empagliflozin) and ... Jardiance and Ofev

  • AZ claims first-in-class win for Farxiga in heart failure AZ claims first-in-class win for Farxiga in heart failure

    AZ in pursuit of class leader Jardiance. AstraZeneca has moved a step close to a chronic heart failure claim for its diabetes drug Farxiga after reporting positive results in a phase ... Sales grew by a third to $1.4bn last year as Farxiga tries to chase

  • Boehringer posts solid first half as business revamp beds in Boehringer posts solid first half as business revamp beds in

    Jardiance helped to boost sales. Strong sales of diabetes therapy Jardiance helped Boehringer Ingelheim to a solid if unspectacular first half, as it shrugged off the continuing impact of generic competition ... Analysts at Evercore ISI have suggested

  • Blow for Entresto in latest heart failure trial Blow for Entresto in latest heart failure trial

    Novartis has faced increasing competition in the heart failure therapy area of late, with Jardiance, Eli Lilly and Boehringer Ingelheim’s SGLT2 inhibitor, recently fast tracked by the FDA for review ... of its use in heart failure in adults with

  • Boehringer bolsters NASH pipeline with $870m Yuhan deal Boehringer bolsters NASH pipeline with $870m Yuhan deal

    linagliptin/metformin) and Jardiance (empagliflozin).  Yuhan has retained rights to the dual agonist in its home market.

More from news
Approximately 21 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics